Polu Krishna R 4
4 · Equillium, Inc. · Filed Apr 24, 2020
Insider Transaction Report
Form 4
Polu Krishna R
Chief Medical Officer
Transactions
- Disposition to Issuer
Stock Option (right to buy)
2020-04-22−208,216→ 0 totalExercise: $3.30Exp: 2028-08-15→ Common Stock (208,216 underlying) - Award
Stock Option (right to buy)
2020-04-22+90,000→ 90,000 totalExercise: $2.45Exp: 2029-02-12→ Common Stock (90,000 underlying) - Disposition to Issuer
Stock Option (right to buy)
2020-04-22−125,000→ 0 totalExercise: $4.75Exp: 2029-12-09→ Common Stock (125,000 underlying) - Award
Stock Option (right to buy)
2020-04-22+125,000→ 125,000 totalExercise: $2.45Exp: 2029-12-09→ Common Stock (125,000 underlying) - Award
Stock Option (right to buy)
2020-04-22+208,216→ 208,216 totalExercise: $2.45Exp: 2028-08-15→ Common Stock (208,216 underlying) - Disposition to Issuer
Stock Option (right to buy)
2020-04-22−90,000→ 0 totalExercise: $7.16Exp: 2029-02-12→ Common Stock (90,000 underlying)
Footnotes (4)
- [F1]Twenty-five percent of the shares subject to the option vests on the first anniversary of the vesting commencement date, and the remainder vests in 36 equal monthly installments thereafter for the following three years.
- [F2]Effective April 22, 2020, the Board of Directors of the Company approved an option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of this option granted to him on August 16, 2018, in exchange for a new option having a lower exercise price of $2.45 per share, which is the closing price of the Company's common stock on April 22, 2020. All of the other terms of the option remained unchanged.
- [F3]Effective April 22, 2020, the Board of Directors of the Company approved an option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of this option granted to him on February 13, 2019, in exchange for a new option having a lower exercise price of $2.45 per share, which is the closing price of the Company's common stock on April 22, 2020. All of the other terms of the option remained unchanged.
- [F4]Effective April 22, 2020, the Board of Directors of the Company approved an option repricing which resulted in, for purposes of Section 16 of the Exchange Act, the cancellation of this option granted to him on December 10, 2019, in exchange for a new option having a lower exercise price of $2.45 per share, which is the closing price of the Company's common stock on April 22, 2020. All of the other terms of the option remained unchanged.